Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria A Rodriguez

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Nature Communications|August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trialPaolo Strati, Lei Feng, Jason R Westin, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Oncology Reports|July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Blood|November 23, 2013
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraZheng Zhou, Laurie H Sehn, Alfred W Rademaker, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Nature Communications|August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trialPaolo Strati, Lei Feng, Jason R Westin, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Oncology Reports|July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Blood|November 23, 2013
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraZheng Zhou, Laurie H Sehn, Alfred W Rademaker, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Pageof 8